RESULTS	O

Forty	O
Caucasians	O
(	O
19	O
females	O
)	O
with	O
essential	O
hypertension	O
were	O
enrolled	O
in	O
the	O
study	O
.	O

Their	O
mean	O
age	O
was	O
57	O
years	O
.	O

Most	O
of	O
them	O
were	O
overweight	O
,	O
17	O
had	O
metabolic	O
syndrome	O
according	O
to	O
the	O
updated	O
AHA	O
NHLBI	O
statement	O
(	O
defined	O
as	O
3	O
or	O
more	O
of	O
the	O
following	O
:	O
waist	O
circumference	O
>	O
102	O
cm	O
in	O
men	O
and	O
>	O
88	O
cm	O
in	O
women	O
,	O
blood	B-Organism_substance
pressure	O
>	O
=	O
130	O
/	O
85	O
mmHg	O
,	O
triglycerides	O
>	O
150	O
mg	O
/	O
dl	O
,	O
HDL	O
-	O
C	O
<	O
40	O
mg	O
/	O
dl	O
in	O
men	O
and	O
<	O
50	O
mg	O
/	O
dl	O
in	O
women	O
,	O
and	O
fasting	O
glucose	O
>	O
=	O
100	O
mg	O
/	O
dl	O
)	O
,	O
8	O
had	O
type	O
2	O
diabetes	O
and	O
18	O
were	O
smokers	O
(	O
Table	O
1	O
)	O
.	O

Eprosartan	O
reduced	O
SBP	O
by	O
8	O
%	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
DBP	O
by	O
13	O
%	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
while	O
it	O
had	O
a	O
neutral	O
effect	O
on	O
the	O
lipid	O
profile	O
and	O
apolipoprotein	O
levels	O
(	O
Table2	O
)	O
.	O

Eprosartan	O
did	O
not	O
affect	O
plasma	B-Organism_substance
8	O
-	O
epiPGF2a	O
levels	O
,	O
whereas	O
it	O
significantly	O
increased	O
by	O
24	O
%	O
the	O
lag	O
time	O
of	O
total	O
serum	B-Organism_substance
oxidation	O
(	O
145	O
+	O
/	O
-	O
54	O
min	O
vs	O
180	O
+	O
/	O
-	O
58	O
min	O
,	O
p	O
=	O
0	O
.	O
001	O
)	O
(	O
Table2	O
)	O
.	O

Eprosartan	O
reduced	O
by	O
14	O
%	O
the	O
aspartate	O
aminotransferase	O
(	O
form	O
21	O
to	O
18	O
U	O
/	O
L	O
,	O
p	O
=	O
0	O
.	O
04	O
)	O
and	O
by	O
21	O
%	O
the	O
alanine	O
aminotransferase	O
(	O
from	O
24	O
to	O
19	O
U	O
/	O
L	O
,	O
p	O
=	O
0	O
.	O
05	O
)	O
activity	O
(	O
Table2	O
)	O
.	O

The	O
administration	O
of	O
eprosartan	O
had	O
no	O
influence	O
on	O
glucose	O
homeostasis	O
,	O
as	O
well	O
as	O
on	O
creatinine	O
and	O
uric	O
acid	O
levels	O
(	O
Table2	O
)	O
.	O

In	O
addition	O
,	O
eprosartan	O
did	O
not	O
affect	O
clotting	O
or	O
fibrinolytic	O
activity	O
as	O
this	O
was	O
estimated	O
by	O
PAI	O
-	O
1	O
,	O
tPA	O
and	O
a2	O
-	O
antiplasmin	O
(	O
Table2	O
)	O
.	O

The	O
enzymatic	O
activity	O
of	O
Lp	O
-	O
PLA2	O
and	O
PON1	O
were	O
not	O
altered	O
significantly	O
following	O
eprosartan	O
treatment	O
(	O
Table2	O
)	O
.	O

